
Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …

Seven new drugs currently in development will enter the market this year – and earn sales of more than $1 …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

